AC
RVMD icon

Aristides Capital’s Revolution Medicines RVMD Stock Holding History

Aristides Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,581
Closed -$284K – 174
2022
Q2 		$284K Hold
14,581
– – 0.19% 105
2022
Q1 		$372K Buy
+14,581
New +$317K 0.23% 102

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Aristides Capital's RVMD Position: Q3 2022 in Review

Aristides Capital sold out of Revolution Medicines (RVMD) in Q3 2022, closing a stake of 14,581 shares — an estimated $284K sold.

Aristides Capital first reported a position in RVMD in Q1 2022 and held it in 2 quarters. The position peaked at $372K in Q1 2022. 142 funds tracked by Wall St. Rank hold RVMD as of Q3 2022.

  • Aristides Capital reported no remaining Revolution Medicines position as of Q3 2022 after selling out during the quarter.
  • Aristides Capital sold 14,581 Revolution Medicines shares in Q3 2022, an estimated $284K.
  • Aristides Capital first reported a position in Revolution Medicines in Q1 2022 and held it in 2 quarters.
  • Aristides Capital's Revolution Medicines position peaked at $372K in Q1 2022.
  • 142 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2022.

Based on Aristides Capital's 13F filing for Q3 2022, filed 15 Nov 2022.